Steven S Gill

US Patent:

7771728, Aug 10, 2010

Filed:

Dec 21, 2006

Appl. No.:

11/614716

Inventors:

Andreas Meinke - Pressbaum, AT
Eszter Nagy - Vienna, AT
Uwe Von Ahsen - Vienna, AT
Christoph Klade - Wr. Neustadt, AT
Tamas Henics - Vienna, AT
Wolfgang Zauner - Vienna, AT
Duc Bui Minh - Vienna, AT
Oresta Vytvytska - Vienna, AT
Hildegard Etz - Vienna, AT
Agnieszka Dryla - Vienna, AT
Thomas Weichhart - Böheimkirchen, AT
Martin Hafner - Vienna, AT
Brigitte Tempelmaier - Vienna, AT
Claire M. Fraser - Potomac MD, US
Steven Gill - Frederick MD, US

Assignee:

Intercell AG - Vienna

International Classification:

A61K 39/085

US Classification:

4241901, 4242431

Abstract:

Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: —providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —screening said at least one expression library with said antibody preparation, —identifying antigens which bind in said screening to antibodies in said antibody preparation, —screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and —optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

US Patent:

7968297, Jun 28, 2011

Filed:

Jan 21, 2002

Appl. No.:

10/470048

Inventors:

Andreas Meinke - Pressbaum, AT
Eszter Nagy - Vienna, AT
Uwe Von Ahsen - Vienna, AT
Christoph Klade - Wr. Neustadt, AT
Tamas Henics - Vienna, AT
Wolfgang Zauner - Vienna, AT
Duc Bui Minh - Vienna, AT
Oresta Vytvytska - Vienna, AT
Hildegard Etz - Vienna, AT
Agnieszka Dryla - Vienna, AT
Thomas Weichhart - Böheimkirchen, AT
Martin Hafner - Vienna, AT
Brigitte Tempelmaier - Vienna, AT
Claire M. Fraser - Potomac MD, US
Steven Gill - Frederick MD, US

Assignee:

Intercell AG - Vienna

International Classification:

G01N 33/53

US Classification:

435 71

Abstract:

Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: —providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —screening said at least one expression library with said antibody preparation, —identifying antigens which bind in said screening to antibodies in said antibody preparation, —screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and —optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

US Patent:

8323660, Dec 4, 2012

Filed:

Aug 9, 2010

Appl. No.:

12/853074

Inventors:

Andreas Meinke - Pressbaum, AT
Eszter Nagy - Vienna, AT
Uwe Von Ahsen - Vienna, AT
Christoph Klade - Wr. Neustadt, AT
Tamas Henics - Vienna, AT
Wolfgang Zauner - Vienna, AT
Duc Bui Minh - Vienna, AT
Oresta Vytvytska - Vienna, AT
Hildegard Etz - Vienna, AT
Agnieszka Dryla - Vienna, AT
Thomas Weichhart - Böheimkirchen, AT
Martin Hafner - Vienna, AT
Brigitre Tempelmaier - Vienna, AT
Claire M. Fraser - Potomac MD, US
Steven Gill - Frederick MD, US

Assignee:

Intercell AG - Vienna

International Classification:

A61K 39/085

US Classification:

4241901, 4242431

Abstract:

Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps:—providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—screening said at least one expression library with said antibody preparation,—identifying antigens which bind in said screening to antibodies in said antibody preparation,—screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and—optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

US Patent:

20130034575, Feb 7, 2013

Filed:

Sep 13, 2012

Appl. No.:

13/613761

Inventors:

Andreas Meinke - Pressbaum, AT
Eszter Nagy - Vienna, AT
Uwe Von Ahsen - Vienna, AT
Christoph Klade - Wr. Neustadt, AT
Tamas Henics - Vienna, AT
Wolfgang Zauner - Vienna, AT
Duc Bui Minh - Vienna, AT
Oresta Vytvytska - Vienna, AT
Hildegard Etz - Vienna, AT
Agnieszka Dryla - Vienna, AT
Thomas Weichhart - Boheimkirchen, AT
Martin Hafner - Vienna, AT
Brigitte Tempelmaier - Vienna, AT
Claire M. Fraser - Potomac MD, US
Steven Gill - Frederick MD, US

Assignee:

Intercell AG - Vienna

International Classification:

A61K 39/00
C07K 16/00
C07K 7/08
C07K 14/00
C07K 7/06

US Classification:

4241851, 530350, 530329, 530328, 530327, 530326, 530324, 536 231, 5303879

Abstract:

Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: providing an antibody preparation, providing at least one expression library, identifying antigens which bind, screening the identified antigens, identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.